

ALL IMAGES VIDEOS

55,700 Results Any time

Efficacy and safety of tenofovir disoproxil fumarate in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824756>

[21] Min IS, Lee CH, Shin IS, et al. Treatment outcome and renal safety of 3-year tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with preserved glomerular filtration rate. *Gut Liver* 2018; 13 :93-103.

Cited by: 1 Author: Shuqin Zhong, Longgen Liu, Jianchun Lu...
Publish Year: 2019

Efficacy of Tenofovir Disoproxil Fumarate Therapy in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451271>

Marcellin P, Gane E, Buti M, Aldhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet*. 2013; 381 (9865):468-75. doi: 10.1016/S0140-6736(12)61425-1.

Cited by: 5 Author: Fatemeh Bakhshizadeh, Soheila Hokmat,...
Publish Year: 2015

Renal tubular dysfunction during long-term adefovir or ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1468888>

Search Tools

Turn off Hover Translation (关闭悬停翻译)

国内版 国际版

Histopathological evaluation of long-term tenofovir disoproxil fuma



ALL IMAGES VIDEOS

28,600 Results

Any time ▾

Open links in new tab



[Considerations for the Long-Term Treatment of Chronic ...](#)

https://www.medscape.org/viewarticle/776011_2 ▾

May 04, 2020 · Duarte-Rojo A, Heathcote EJ. Efficacy and safety of **tenofovir disoproxil fumarate** in **patients** with **chronic hepatitis B**. *Therap. Adv. Gastroenterol.* 3(2),107– 119(2010). Woo G, Tomlinson G, Nishikawa Y et al . **Tenofovir** and entecavir are the most effective antiviral agents for **chronic hepatitis B**: a systematic review and Bayesian meta-analyses.

[Current and Emerging Therapies for Chronic Hepatitis B](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950623>

Study 107 is a randomized trial evaluating fixed-dose emtricitabine (FTC)/**tenofovir disoproxil fumarate** (TDF) with or without **hepatitis B** immune globulin (HBIG) for the prevention of **hepatitis B** recurrence in **patients** undergoing orthotopic liver transplantation (OLT). 2 The trial enrolled 40 **patients** with CHB who had undergone OLT and had received at least 12 weeks of prophylactic therapy ...

Author: Robert S Brown Publish Year: 2010

[Safety and efficacy of stopping tenofovir disoproxil ...](#)

[https://www.thelancet.com/journals/langas/article/PIIS2468-1253\(19\)30015-9/fulltext](https://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30015-9/fulltext)

4 Name of Journal: *World Journal of Gastrointestinal Pharmacology and Therapeutics*

Manuscript NO: 61779

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Histopathological evaluation of long-term tenofovir disoproxil fumarate treatment in patients with hepatitis be antigen-negative chronic hepatitis B

Bahri Abayli, Cansu Abayli, Genco Gencdal

Match Overview

1	Internet 120 words crawled on 06-Jan-2017 www.wjgnet.com	4%
2	Internet 67 words crawled on 25-Mar-2019 aasldpubs.onlinelibrary.wiley.com	2%
3	Internet 37 words crawled on 25-Mar-2015 www.nalap.org	1%
4	Internet 17 words crawled on 01-Nov-2019 fbpublishing.blob.core.windows.net	1%
5	Internet 16 words crawled on 19-Oct-2019 www.cureus.com	1%

国内版 国际版

Histopathological evaluation of long-term tenofovir disoproxil fuma



ALL IMAGES VIDEOS

28,400 Results Any time ▾

Current and Emerging Therapies for Chronic Hepatitis B

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950623>

Study 107 is a randomized trial evaluating fixed-dose emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) with or without hepatitis B immune globulin (HBIG) for the prevention of hepatitis B recurrence in patients undergoing orthotopic liver transplantation (OLT). 2 The trial enrolled 40 patients with CHB who had undergone OLT and had received at least 12 weeks of prophylactic therapy ...

Author: Robert S Brown Publish Year: 2010

Regression of cirrhosis during treatment with tenofovir ...

[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(12\)61425-1/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61425-1/fulltext)

We searched PubMed with the search terms "antiviral agents", "hepatitis B, chronic/drug therapy", "liver cirrhosis/pathology", "tenofovir disoproxil fumarate", "adefovir dipivoxil", "lamivudine", and "entecavir" for randomised controlled trials and other long-term clinical trials ...

Cited by: 1407 Author: Patrick Marcellin, Edward J Gane, Maria ...

Publish Year: 2013

New approaches in the management of chronic hepatitis B ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108728>

Heathcote EJ, Gane E, De Man R, Chan S, Sievert W, Mauss S, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis. Hepatology. 2008; 48 (Suppl 1):A158.

Cited by: 6 Author: Jurriën Gp Reijnders, Harry La Janssen

Publish Year: 2009

Safety and efficacy of stopping tenofovir disoproxil ...

[https://www.thelancet.com/journals/langas/article/PIIS2468-1253\(19\)30015-9/fulltext](https://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30015-9/fulltext)

Studies GS-US-174-102 (hepatitis B e antigen [HBeAg]-negative patients) and GS-US-174-103 (HBeAg-positive patients) are among the longest studies of potent antiviral therapy for chronic hepatitis B with nucleos(t)ide analogues and show that 99% of patients remaining on tenofovir disoproxil fumarate (TDF) therapy achieve and maintain undetectable concentrations of HBV DNA after up to 8 years of ...

Cited by: 10 Author: Maria Buti, David K Wong, Edward Gane,...

Publish Year: 2019